Thematic Exposure -- 7/10
Medtronic is a high-quality oligopolist with one genuinely strong, growing franchise carrying a
diversified but more contested rest-of-book. The standout is Cardiovascular — specifically CRHF and
the cardiac-ablation/PFA franchise — where MDT holds >30% share in cardiac ablation and is a clear
top-two player in a concentrated market re-accelerating on PFA adoption (~26% CAGR). It clears the
oligopoly gate, so no 5/10 cap applies. It falls short of 8-10 because no single segment delivers a
dominant >50% share — the rest is a collection of strong #2 positions (stapling behind J&J, DBS
roughly tied with Abbott/BSX, share donor in diabetes).
Weight: 35%
Cardiovascular / PFA-Affera -- Strong Theme
Secular Tailwind -- Concentrated, Re-Accelerating
Cardiovascular (~39% of revenue, CRHF ~22%) is MDT's growth engine and the anchor of the thesis.
MDT is top-two in a concentrated CRM market (MDT + BSX >50%) and held >30% share in broader
cardiac ablation in 2025, with Affera/PFA growing +78% global, +124% U.S., and gaining +8pts of
U.S. share. The PFA market is compounding ~26% CAGR to 2031 — a genuine, durable secular tailwind
inside an oligopolistic structure.
Oligopolist -- But Not a >50% Monopolist
Rest-of-Book: Strong #2 Positions
Outside Cardiovascular, MDT is a collection of strong #2 positions: #2 in surgical stapling behind
J&J/Ethicon (~24% vs ~31%), roughly co-equal #2-3 in neuromodulation/DBS (Abbott ~15%, MDT ~14%,
BSX ~13%, but top-3 >80%), and a diabetes franchise where MiniMed still holds the largest installed
base (~40%) but is ceding flow share to Tandem and Insulet. No single segment delivers a dominant
>50% category monopoly — which caps the score below 8.
Diabetes -- Structural Substitution Risk
Share Donor -- Being Separated
The highest-growth diabetes theme (insulin pumps ~$4.3B in 2024 to ~$7.3B by 2030, ~9% CAGR) is one
where MDT is under-indexed and actively losing share. Tubeless AID (Omnipod 5) and GLP-1-driven
demand shifts are eroding MDT's lead — the genuine multi-year substitution risk in the portfolio,
and why MDT is separating MiniMed via IPO + split.
Segment revenue mix (FY2026Q4)
Thematic exposure by segment
| Segment | % Rev | Market Share | Theme Growth |
|---|---|---|---|
| Cardiovascular / CRHF | ~39% (CRHF ~22%) | Top-2; MDT + BSX >50% of CRM. Leader in ICDs/pacemakers. >30% cardiac-ablation share in 2025 (Affera/PFA +78% global, +124% U.S., +8pts share) | CRM low-single; PFA/ablation high — ~26% CAGR to 2031 |
| Neuroscience (incl. DBS) | ~28% | DBS fragmented at top: Abbott ~15%, MDT ~14%, BSX ~13%, but top-3 >80%. MDT leads cranial/spinal navigation | Neuromodulation ~11% CAGR; mid-single-digit organic |
| Medical Surgical | ~24% | #2 in surgical stapling: J&J/Ethicon ~31%, MDT ~24%; Intuitive expanding into stapling | Stapling ~mid-single; pressured by robotic share shift |
| Diabetes (MiniMed) | ~9% | MiniMed ~40% of insulin-pump installed base (2025) but losing flow share to Tandem & Insulet/Omnipod | ~9% CAGR theme, but MDT under-indexed (share donor) |
Competitors by segment: Cardiovascular/CRM — Boston Scientific, Abbott, Biotronik; PFA — Boston
Scientific (Farapulse, ~70% PFA today), J&J (Varipulse), Abbott (Volt, pending). Neuromodulation —
Abbott, Boston Scientific, Nevro, LivaNova. Surgical — J&J/Ethicon, Intuitive Surgical, B. Braun,
Conmed. Diabetes — Tandem, Insulet, Ypsomed, Roche.
Oligopoly Gate
| Criterion | Result |
|---|---|
| MDT share in cardiac ablation (2025) | >30% |
| CRM concentration (MDT + BSX) | >50% (≤2 players) |
| Any segment fragmented (>5 players >15%)? | No |
| Gate result | PASS |
7/10 — MDT clears the oligopoly gate:
>30% share in cardiac ablation and one of ≤2 players (with BSX) controlling >50% of cardiac rhythm
management, its largest sub-segment; in DBS the top-3 (incl. MDT) control >80%. No 5/10 fragmentation
cap applies. The moat — trained installed base, clinical evidence, hospital relationships, regulatory
barriers — is durable with no 12-month substitution risk. It falls short of 8-10 because no single
segment delivers a dominant >50% share, the rest of the portfolio is a collection of #2 positions, and
the highest-growth diabetes theme is one MDT is losing and divesting.
Data sourced from Daloopa (company_id 483).